Abstract |
Four of 10 patients who were enrolled on protocols of high-dose immunosuppression with peripheral blood stem cell rescue for MS experienced neurologic worsening while receiving recombinant human granulocyte colony-stimulating factor. There was improvement when methylprednisolone was given to three of the patients, but one patient died of respiratory failure. The mechanism of the neurologic worsening is uncertain.
|
Authors | H Openshaw, O Stuve, J P Antel, R Nash, B T Lund, L P Weiner, A Kashyap, P McSweeney, S Forman |
Journal | Neurology
(Neurology)
Vol. 54
Issue 11
Pg. 2147-50
(Jun 13 2000)
ISSN: 0028-3878 [Print] United States |
PMID | 10851379
(Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Anti-Inflammatory Agents
- Recombinant Proteins
- Granulocyte Colony-Stimulating Factor
- Methylprednisolone
|
Topics |
- Adult
- Anti-Inflammatory Agents
(therapeutic use)
- Female
- Granulocyte Colony-Stimulating Factor
(adverse effects)
- Hematopoietic Stem Cell Transplantation
(adverse effects)
- Humans
- Male
- Methylprednisolone
(therapeutic use)
- Middle Aged
- Multiple Sclerosis
(drug therapy)
- Paralysis
(chemically induced, drug therapy)
- Recombinant Proteins
|